08/16/2021 18:49
Clarín.com
Society
Updated 08/16/2021 6:49 PM
The
coronavirus
vaccine
being developed jointly by Conicet and the University of San Martín (Unsam) will be used as a "booster",
a reinforcement of others
, and trials with phase 1 volunteers
could begin in early 2022
, he said. this Monday the president of the National Agency for the Promotion of Research, Technological Development and Innovation (R + D + i), Fernando Peirano.
The official highlighted that the project of the Argentine vaccine against covid-19
"Arvac Cecilia Grierson"
, directed by Juliana Cassataro, of the team of the Institute of Biotechnological Investigations of the National University of San Martín and Conicet, is
"the one that is advancing faster "
.
"The expectation is that work on volunteers will begin early next year, that is, phase 1, to
test the safety and efficacy
of this vaccine," Peirano said in a dialogue with radio AM 750.
The vaccine under development is the first project selected by the National Agency for the Promotion of Research, Technological Development and Innovation (R + D + i Agency) within the framework of the Coronavirus Unit that it integrates together with the Ministry of Science, Technology and Innovation of the Nation and the Conicet.
In June, the R + D + i Agency approved a support of
60,000,000 pesos
to conclude the preclinical stage of carrying out the corresponding safety and immune capacity tests and move towards the clinical stages that evaluate the safety and efficacy of the "Arvac Cecilia Grierson "in humans.
"It is intended to be a booster, that is to say
a reinforcement
," Peirano explained and estimated that it could be used to extend the vaccination schedule "including a regular vaccine against coronavirus."
In that sense, he stressed the importance of this regular vaccine "being designed, produced and applied in Argentina, and also in Latin America and other countries in the world."
The interdisciplinary group of researchers obtained two vaccine prototypes that in studies in animal models demonstrated the ability to induce very good levels of virus neutralizing antibodies and T cell immune response, in line with current requirements for vaccines that prevent Covid-19.
On the other hand, the official remarked that the vaccine under development "Arvac Cecilia Grierson" is not the only project, but that "there are others in progress that are coming back and we are finishing evaluating them to give them strong support, the support of resources. necessary to go through the preclinical phase ".
With information from Télam
DD
Look also
Scandal in Salta: three arrested for falsifying recipes to vaccinate adolescents against the coronavirus
Why Uruguay began to apply a third booster dose against the coronavirus
Babies and youngsters are more infectious at home than adolescents